Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06559189 · ClinicalTrials.gov registry record · Phase 1
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
A Phase 1 study of B-cell Acute Lymphoblastic Leukemia, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT06559189 is a Phase 1 study of B-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 53 participants, below the 86-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06559189, a Phase 1 study of B-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
Conditions Studied
Interventions
- BIOLOGICAL CD19x22 CAR T
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06559189
The ClinicalTrials.gov registry entry for NCT06559189 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (38% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CD19x22 CAR T is the first listed.
NCT06559189 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06559189 about?
NCT06559189 is a clinical study titled "CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL". This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
What is the current status of trial NCT06559189?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2024-09-27. Estimated completion is 2029-12.
What conditions does trial NCT06559189 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT06559189?
The interventions under investigation include: CD19x22 CAR T (BIOLOGICAL).
Who is sponsoring clinical trial NCT06559189?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06559189 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
RECRUITING · Phase 1
-
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
RECRUITING · Phase 1
-
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RECRUITING · Phase 1
-
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.